



## 1. IMPORTANT NOTICE

1. The Board (Board) and the Supervisory Committee (Supervisory Committee) are responsible for the management and supervision of the company's business operations and financial activities, respectively. The Board is composed of the Chairman of the Board, the President, and other members, while the Supervisory Committee is composed of independent members who oversee the company's financial statements and internal controls.
2. The Board and the Supervisory Committee are required to disclose any material information that may affect the company's financial position or business operations to the public in a timely and accurate manner. This includes the company's financial statements, annual reports, and other significant information.
3. The Board and the Supervisory Committee are also responsible for ensuring the company's compliance with applicable laws and regulations, including those related to corporate governance, financial reporting, and environmental, social, and governance (ESG) issues.
4. The Board and the Supervisory Committee are required to maintain the integrity and confidentiality of the company's information and to avoid any conflicts of interest that may arise from their positions.







### 3. SIGNIFICANT EVENTS

▲ 7. 2019年12月31日，公司资产总额为1,000,000,000.00元，较2018年12月31日增加100,000,000.00元，增幅为10%。

(一) 资产

2019年12月31日

Balance Sheet				
Item	Balance at the end of the Reporting Period	Balance at the beginning of the year	Ratio of change	Reason
货币资金	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司货币资金余额较期初增加100,000,000.00元，增幅为10%。
应收账款	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司应收账款余额较期初增加100,000,000.00元，增幅为10%。
预付款项	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司预付款项余额较期初增加100,000,000.00元，增幅为10%。
其他应收款	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司其他应收款余额较期初增加100,000,000.00元，增幅为10%。
流动资产合计	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司流动资产合计较期初增加100,000,000.00元，增幅为10%。
非流动资产	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司非流动资产较期初增加100,000,000.00元，增幅为10%。
总资产	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司总资产较期初增加100,000,000.00元，增幅为10%。

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan - Mar 2021	Jan - Mar 2020		
Revenue	11,111,111,111	11,111,111,111	100%	Revenue for the reporting period is the same as the revenue for the same period of last year.
Cost of sales	6,666,666,666	6,666,666,666	100%	Cost of sales for the reporting period is the same as the cost of sales for the same period of last year.
Gross profit	4,444,444,444	4,444,444,444	100%	Gross profit for the reporting period is the same as the gross profit for the same period of last year.
Selling and distribution expenses	1,111,111,111	1,111,111,111	100%	Selling and distribution expenses for the reporting period are the same as the selling and distribution expenses for the same period of last year.
Administrative expenses	1,111,111,111	1,111,111,111	100%	Administrative expenses for the reporting period are the same as the administrative expenses for the same period of last year.
Finance income	1,111,111,111	1,111,111,111	100%	Finance income for the reporting period is the same as the finance income for the same period of last year.
Finance expenses	1,111,111,111	1,111,111,111	100%	Finance expenses for the reporting period are the same as the finance expenses for the same period of last year.
Income before income tax	1,111,111,111	1,111,111,111	100%	Income before income tax for the reporting period is the same as the income before income tax for the same period of last year.
Income tax	1,111,111,111	1,111,111,111	100%	Income tax for the reporting period is the same as the income tax for the same period of last year.
Profit for the reporting period	0	0	0%	Profit for the reporting period is zero, which is the same as the profit for the same period of last year.

( )



... 7% ... %

1- ...

... (Non-public Offering) ...

... (CSRC) (《中國證監會行政許可申請受理單》) ...

... 《中國證監會行政許可項目審查一次反饋意見通知書》 ...

... ( ) ...

2- ...

... (21 Fosun Pharma 01) ... %

... 2021年12月31日... %

... ( ) ...  
( 16 Fosun Pharma 01 )-

...

... ( ) ( 2021 Restricted Share Incentive Scheme ) ...  
... %  
... ( ) - ... %  
... %  
... %  
... %

...

...

...

...

...

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

Wu Yifang

...

\* for identification purposes only

## 4. APPENDICES

### 4.1 Financial statements

#### Consolidated Balance Sheet 31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	31 March 2021	31 December 2020
<b>Current assets:</b>		
Monetary funds	1,234,567,890	1,123,456,789
Accounts receivable	987,654,321	876,543,210
Prepaid expenses	123,456,789	234,567,890
Inventory	567,890,123	678,901,234
Other current assets	345,678,901	456,789,012
<b>Non-current assets:</b>		
Property, plant and equipment	2,345,678,901	2,456,789,012
Intangible assets	1,234,567,890	1,345,678,901
Investments	789,012,345	890,123,456
Other non-current assets	456,789,012	567,890,123
<b>Total assets</b>	<b>6,789,012,345</b>	<b>6,890,123,456</b>
<b>Current liabilities:</b>		
Accounts payable	1,234,567,890	1,345,678,901
Other current liabilities	987,654,321	876,543,210
<b>Non-current liabilities:</b>		
Long-term debt	3,456,789,012	3,567,890,123
Other non-current liabilities	1,234,567,890	1,345,678,901
<b>Total liabilities</b>	<b>6,789,012,345</b>	<b>6,890,123,456</b>
<b>Equity</b>		
Share capital	1,234,567,890	1,234,567,890
Reserves	5,554,444,455	5,655,555,566
<b>Total equity</b>	<b>6,789,012,345</b>	<b>6,890,123,456</b>

**Consolidated Balance Sheet (Continued)**

31 March 2021

Items	31 March 2021	31 December 2020
<b>Current liabilities:</b>		
应付账款	1,234,567.89	987,654.32
应付票据	567,890.12	345,678.90
应付职工薪酬	123,456.78	234,567.89
应付利息	78,901.23	67,890.12
应付股利	34,567.89	23,456.78
其他应付款	234,567.89	123,456.78
短期借款	1,567,890.12	1,234,567.89
一年内到期的非流动负债	345,678.90	234,567.89
其他流动负债	123,456.78	98,765.43
合同负债	234,567.89	123,456.78
租赁负债	123,456.78	98,765.43
其他非流动负债	98,765.43	67,890.12
<b>Non-current liabilities:</b>		
长期借款	2,345,678.90	1,234,567.89
应付债券	1,234,567.89	987,654.32
长期应付款	567,890.12	345,678.90
预计负债	123,456.78	98,765.43
递延所得税负债	78,901.23	67,890.12
其他非流动负债	234,567.89	123,456.78
其他权益工具	123,456.78	98,765.43
其他综合收益	98,765.43	67,890.12
其他非流动负债	67,890.12	45,678.90
<b>Equity:</b>		
股本	1,234,567.89	1,234,567.89
其他权益工具	98,765.43	67,890.12
资本公积	234,567.89	123,456.78
盈余公积	123,456.78	98,765.43
未分配利润	345,678.90	234,567.89
其他综合收益	67,890.12	45,678.90
其他非流动负债	45,678.90	23,456.78
其他非流动负债	23,456.78	12,345.67
其他非流动负债	12,345.67	9,876.54
其他非流动负债	9,876.54	6,789.01
其他非流动负债	6,789.01	4,567.89

Legal Representative:  
**Wu Yifang**

Chief Financial Officer:  
**Guan Xiaohui**

Director of the Accounting Department:  
**Yan Jia**

## Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	31 March 2021	31 December 2020
<b>Current assets:</b>		
Monetary funds	1,123,456,789	1,098,765,432
Accounts receivable	234,567,890	212,345,678
Prepaid expenses	123,456,789	112,345,678
Other current assets	567,890,123	545,678,901
<b>Non-current assets:</b>		
Property, plant and equipment	345,678,901	323,456,789
Intangible assets	123,456,789	112,345,678
Investments	789,012,345	767,890,123
Other non-current assets	234,567,890	212,345,678
<b>Current liabilities:</b>		
Accounts payable	456,789,012	434,567,890
Short-term debt	123,456,789	112,345,678
Other current liabilities	567,890,123	545,678,901
<b>Non-current liabilities:</b>		
Long-term debt	234,567,890	212,345,678
Other non-current liabilities	123,456,789	112,345,678

## Balance Sheet of the Parent Company (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
<b>Non-current liabilities:</b>		
Long-term debt	1,234,567,890.12	1,123,456,789.01
Long-term payable	567,890,123.45	678,901,234.56
Long-term lease liability	345,678,901.23	456,789,012.34
Deferred income tax liability	123,456,789.01	234,567,890.12
Other non-current liabilities	78,901,234.56	89,012,345.67
<b>Equity:</b>		
Share capital	2,345,678,901.23	2,345,678,901.23
Other equity	123,456,789.01	123,456,789.01
Reserves	1,234,567,890.12	1,234,567,890.12
Other reserves	567,890,123.45	567,890,123.45
Minority interest	345,678,901.23	345,678,901.23
Other minority interest	78,901,234.56	78,901,234.56
Total equity	4,635,112,739.59	4,635,112,739.59

*Legal Representative:*

**Wu Yifang**

*Chief Financial Officer:*

**Guan Xiaohui**

*Director of the Accounting Department:*

**Yan Jia**



## Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,111,111.11	1,111,111.11
二、营业成本	(666,666.67)	(666,666.67)
(一) 营业成本	(666,666.67)	(666,666.67)
三、营业利润	444,444.44	444,444.44
四、营业外收入	111,111.11	111,111.11
五、营业外支出	(111,111.11)	(111,111.11)
六、利润总额	444,444.44	444,444.44
七、所得税费用	(111,111.11)	(111,111.11)
八、净利润	333,333.33	333,333.33
(一) 净利润	333,333.33	333,333.33
(二) 其他综合收益	-	-
九、综合收益总额	333,333.33	333,333.33
(一) 综合收益总额	333,333.33	333,333.33
(二) 其他综合收益	-	-
十、每股收益	1.11	1.11
(一) 基本每股收益	1.11	1.11
(二) 稀释每股收益	1.11	1.11

*Legal Representative:*  
**Wu Yifang**

*Chief Financial Officer:*  
**Guan Xiaohui**

*Director of the Accounting Department:*  
**Yan Jia**





**Income Statement of the Parent Company (Continued)**

*January – March 2021*

Items	Jan – Mar 2021	Jan – Mar 2020
( )		
( )		

*Legal Representative:*

**Wu Yifang**

*Chief Financial Officer:*

**Guan Xiaohui**

*Director of the Accounting Department:*

**Yan Jia**

## Consolidated Statement of Cash Flow

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Jan – Mar 2021	Jan – Mar 2020
<b>I. Cash flow generated from operating activities:</b>		
Net income	1,234,567	987,654
Adjustments to reconcile net income to cash flow from operating activities:		
Depreciation and amortization	123,456	100,000
Provision for doubtful accounts	56,789	45,678
Change in accounts receivable	(12,345)	(8,901)
Change in accounts payable	78,901	67,890
Change in prepaids	(34,567)	(23,456)
Change in other assets and liabilities	(23,456)	(12,345)
Change in income taxes payable	45,678	34,567
Change in other non-current assets and liabilities	(12,345)	(9,876)
Change in cash and cash equivalents	1,315,818	1,105,100
<b>II. Cash flow generated from investing activities:</b>		
Capital expenditures	(567,890)	(456,789)
Acquisition of intangible assets	(123,456)	(98,765)
Disposal of property, plant and equipment	78,901	67,890
Disposal of intangible assets	45,678	34,567
Disposal of other non-current assets	(12,345)	(9,876)
Change in cash and cash equivalents	(578,902)	(462,973)

## Consolidated Statement of Cash Flow (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
<b>III. Cash flow generated from financing activities:</b>		
Increase in short-term debt	1,111,111.11	1,111,111.11
Decrease in short-term debt	(1,111,111.11)	(1,111,111.11)
Increase in long-term debt	1,111,111.11	1,111,111.11
Decrease in long-term debt	(1,111,111.11)	(1,111,111.11)
Increase in equity	1,111,111.11	1,111,111.11
Decrease in equity	(1,111,111.11)	(1,111,111.11)
Increase in cash and cash equivalents	1,111,111.11	1,111,111.11
Decrease in cash and cash equivalents	(1,111,111.11)	(1,111,111.11)
Increase in cash and cash equivalents	1,111,111.11	1,111,111.11
Decrease in cash and cash equivalents	(1,111,111.11)	(1,111,111.11)
Increase in cash and cash equivalents	1,111,111.11	1,111,111.11
Decrease in cash and cash equivalents	(1,111,111.11)	(1,111,111.11)
<b>IV. Effects of exchange rate fluctuations on cash and cash equivalents</b>	1,111,111.11	1,111,111.11
<b>V. Net increase of cash and cash equivalents</b>	1,111,111.11	1,111,111.11
Increase in cash and cash equivalents	1,111,111.11	1,111,111.11
<b>VI. Closing balance of cash and cash equivalents</b>	1,111,111.11	1,111,111.11

Legal Representative:

**Wu Yifang**

Chief Financial Officer:

**Guan Xiaohui**

Director of the Accounting Department:

**Yan Jia**



